Cancer Family
Endocrine Neoplasm
CI-CAN-00000015Explore in graph →
Non-malignant762 active trials16 approved drugs64 evidence items
- NCIt
- C3010
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000015Explore in graph →
Clinical trials
2,724 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07177937 | A Study of DXC014 in Patients With Advanced Solid Tumors. | recruiting | Phase 1 | 150 | Hangzhou DAC Biotechnology Co., Ltd.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07365241 | A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer | recruiting | Phase 3 | 531 | AbbVieINDUSTRY | 10 | Sep 23, 2026 | clinicaltrials |
| NCT07835906 | 68Ga-NYM215 in NENs | not yet recruiting | Phase 1 / Phase 2 | 40 | Peking Union Medical College HospitalOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT00001452 | Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex | completed | — | 1,387 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT00001595 | An Investigation of Pituitary Tumors and Related Hypothalmic Disorders | recruiting | — | 2,000 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT00004847 | Diagnosis of Pheochromocytoma | recruiting | Phase 1 | 3,000 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT01005654 | Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms | recruiting | — | 2,415 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT01660984 | Natural History Study of Children and Adults With Medullary Thyroid Cancer | active not recruiting | — | 105 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT02471352 | Studies of Dermatologic Diseases Biospecimen Acquisition Protocol | recruiting | — | 700 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03375320 | Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors | active not recruiting | Phase 3 | 298 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT04079712 | Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors | active not recruiting | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 2 | Sep 22, 2026 | clinicaltrials |
| NCT04522570 | Thermal Ablation of Cervical Metastases From Thyroid Carcinoma | completed | N/A | 84 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06066138 | A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06814496 | Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors(RABBIT) | recruiting | Phase 1 / Phase 2 | 30 | University of ArizonaOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07006727 | Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors | recruiting | Phase 1 | 116 | Novartis PharmaceuticalsINDUSTRY | 4 | Sep 22, 2026 | clinicaltrials |
| NCT07278479 | Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors | recruiting | Phase 1 / Phase 2 | 138 | Molecular Partners AGINDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07833839 | ZG005 Plus Etoposide and Cisplatin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine Carcinoma | not yet recruiting | Phase 3 | 440 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07835412 | A Comparative Study of Patients Undergoing Surgery for Pituitary Neuroendocrine Tumors Detected by Different Ways | recruiting | — | 5,000 | Beijing Tiantan HospitalOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT04429087 | A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 | active not recruiting | Phase 1 | 306 | Boehringer IngelheimINDUSTRY | 4 | Sep 21, 2026 | clinicaltrials |
| NCT05153239 | Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) | completed | Phase 3 | 705 | PharmaMarINDUSTRY | 24 | Sep 21, 2026 | clinicaltrials |
| NCT05578326 | Study of Trilaciclib and Lurbinectidin | recruiting | Phase 2 | 30 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05983432 | Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors | recruiting | Phase 1 | 540 | SystImmune Inc.INDUSTRY | 5 | Sep 21, 2026 | clinicaltrials |
| NCT06021626 | A Study of CRD3874-SI in People With Solid Tumors | recruiting | Phase 1 | 81 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06176989 | Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors | recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06773910 | BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)(TIGOS-LS) | active not recruiting | Phase 2 | 250 | SCRI Development Innovations, LLCOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT03950609 | Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors | active not recruiting | Phase 2 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04234568 | Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors | active not recruiting | Phase 1 | 31 | National Cancer Institute (NCI)NIH | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04665856 | Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer(SKYSCRAPER-02C) | completed | Phase 3 | 123 | Hoffmann-La RocheINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06900595 | Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer | recruiting | Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07743138 | STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL) | not yet recruiting | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04152499 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)(MK-2870-001) | active not recruiting | Phase 1 / Phase 2 | 1,410 | Klus Pharma Inc.INDUSTRY | 6 | Sep 17, 2026 | clinicaltrials |
| NCT04342429 | Prospective Study of Intensity-Modulated Proton Therapy (IMPT) for Small Cell Lung Cancer | recruiting | N/A | 30 | Emory UniversityOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04544111 | PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer | active not recruiting | Phase 2 | 19 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04665739 | Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors | recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04969926 | Natural History Study of Parathyroid Disorders | recruiting | — | 3,000 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06287775 | Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06816394 | Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS)(TAURUS) | recruiting | Phase 2 | 32 | National Taiwan University HospitalOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07459634 | A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC | recruiting | Phase 2 | 50 | Jazz PharmaceuticalsINDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07576725 | Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial | not yet recruiting | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07625644 | BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) | recruiting | Phase 3 | 550 | SystImmune Inc.INDUSTRY | 14 | Sep 17, 2026 | clinicaltrials |
| NCT07778316 | Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)(DeLLphi-315) | recruiting | Phase 3 | 400 | AmgenINDUSTRY | 5 | Sep 17, 2026 | clinicaltrials |
| NCT04467021 | Cancer and Blood Pressure Management, CARISMA Study | active not recruiting | N/A | 61 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06077500 | DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer(DAREONᵀᴹ-8) | active not recruiting | Phase 1 | 46 | Boehringer IngelheimINDUSTRY | 8 | Sep 16, 2026 | clinicaltrials |
| NCT06873555 | A Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 60 | Heronova PharmaceuticalsINDUSTRY | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06878664 | Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors(RIALTO) | recruiting | Phase 3 | 166 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 2 | Sep 16, 2026 | clinicaltrials |
| NCT07080242 | Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors | recruiting | Phase 1 | 120 | SystImmune Inc.INDUSTRY | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07140757 | Radiofrequency Ablation for Management of Benign/Indeterminate Thyroid Nodules and Low Risk Papillary Thyroid Cancers | recruiting | — | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07817225 | Optimizing Risk Assessment Through cfDNA in Pancreatic Neuroendocrine Tumors for Clinical Evaluation(ORACLE) | active not recruiting | — | 30 | Massimo FalconiOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07823439 | Pattern and Surgical Outcome of Papillary Thyroid Cancer at Sohag University Hospitals | not yet recruiting | — | 30 | Sohag UniversityOTHER | 0 | Sep 16, 2026 | clinicaltrials |
| NCT04104529 | Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department(BCB RIV) | recruiting | N/A | 350 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Sep 15, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 23, 2026source: clinicaltrials